TIGIT Antibody (2F7) - VHH - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-12832

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-12832
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Llama Clone # 2F7

Format

Azide and BSA Free

Concentration

1 mg/ml

View all TIGIT Antibodies »

Product Specifications

Immunogen

TIGIT antibody was raised against a recombinant protein corresponding to amino acids 22-141 of human TIGIT.

Clonality

Monoclonal

Host

Llama

Description

Recombinant Monoclonal Antibody - Llamabody(TM). Llama VHH domain containing a Myc-tag for detection and His-tag (MW ~ 15kDa)

Scientific Data Images for TIGIT Antibody (2F7) - VHH - Azide and BSA Free

Immunocytochemistry/ Immunofluorescence: TIGIT Antibody (2F7) - VHH - Azide and BSA Free [NBP3-12832]

Immunocytochemistry/ Immunofluorescence: TIGIT Antibody (2F7) - VHH - Azide and BSA Free [NBP3-12832]

Immunocytochemistry/Immunofluorescence: TIGIT Antibody (2F7) - VHH [NBP3-12832] - Immunofluorescence of TIGIT in human spleen tissue with TIGIT single domain antibody at 20 ug/mL.
Immunohistochemistry: TIGIT Antibody (2F7) - VHH - Azide and BSA Free [NBP3-12832]

Immunohistochemistry: TIGIT Antibody (2F7) - VHH - Azide and BSA Free [NBP3-12832]

Immunohistochemistry: TIGIT Antibody (2F7) - VHH [NBP3-12832] - Immunohistochemistry of TIGIT in human spleen tissue with TIGIT single domain antibody at 1 ug/mL.
Flow Cytometry: TIGIT Antibody (2F7) - VHH - Azide and BSA Free [NBP3-12832]

Flow Cytometry: TIGIT Antibody (2F7) - VHH - Azide and BSA Free [NBP3-12832]

Flow Cytometry: TIGIT Antibody (2F7) - VHH [NBP3-12832] - Flow cytometry analysis of TIGIT overexpressing HEK293 cells using TIGIT single domain antibody and control 1H4 single domain antibody at 0.05 ug/ml. Blue: Untransfected HEK293 cells. Yellow: TIGIT overexpressing HEK293 cells.
View 7 more images

Applications for TIGIT Antibody (2F7) - VHH - Azide and BSA Free

Application
Recommended Usage

ELISA

0.1 ug/mL

Flow Cytometry

1 ug/mL

Immunocytochemistry/ Immunofluorescence

10-20 ug/mL

Immunohistochemistry

10 ug/mL

Formulation, Preparation, and Storage

Purification

Affinity purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: TIGIT

TIGIT (T cell Immunoreceptor with Ig and ITIM domains), also called Vstm3 (V-set and transmembrane domain-containing 3), Vsig9 (V-set and Ig domain-containing 9) and WUCAM (Washington University cell adhesion molecule), is a 30-34 kDa type I transmembrane protein that is a member of the CD28 family within the Ig superfamily of proteins (1-3). Human TIGIT cDNA encodes 244 amino acids (aa) including a 21 aa signal sequence, a 120 aa extracellular region with a V-type Ig-like domain and two potential N-glycosylation sites, a 21 aa transmembrane sequence, an 82 aa cytoplasmic domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and has a theoretical molecular weight of ~27 kDa (3). TIGIT is expressed as a homodimer receptor on NK cells and subsets of activated, memory and regulatory T (Treg) cells, and on follicular helper T cells within secondary lymphoid organs (4). TIGIT has three known homodimer ligands that belong to the nectin family that are expressed on antigen presenting cells (APCs) or tumor cells (5). CD155 is the primary ligand for TIGIT, but it is also capable of binding CD112 and CD113 (5). The CD155/TIGIT signaling axis is an emerging immune checkpoint that inhibits function of T cells and NK cells. Upon TIGIT ligation, CD155 signaling leads to increased secretion of interleukin 10 (IL-10) and decreased secretion of proinflammatory cytokine IL-12 (5). TIGIT is a promising target for cancer immunotherapy and is the center of many pre-clinical studies investigating checkpoint blockade utilizing monoclonal antibodies either as a monotherapy or combination therapy (5).

TIGIT is commonly used as a marker for T cell exhaustion and its expression correlates with disease progression. Furthermore, in viral infections including HIV and SIV, TIGIT serves as a target for immune restoration (6). In cancer detection, TIGIT is upregulated and coexpressed with programmed cell death protein 1 (PD-1) on the majority of circulating tumor antigen (TA)-specific CD8+ T cells (7). In addition to this, TIGIT can inhibit immune cells at multiple steps within the cancer immunity cycle. These include inhibiting NK cell effector function, suppressing dendritic cell costimulatory abilities, suppressing CD8+ T cell effector function by Tregs or polio virus receptor (PVR)-stimulated myeloid cells, and by directly inhibiting CD8+ T cells and preventing elimination of cancer cells (7).

References

1. Joller, N., & Kuchroo, V. K. (2017). Tim-3, Lag-3, and TIGIT. Current topics in microbiology and immunology, 410, 127-156. https://doi.org/10.1007/82_2017_62

2. Xu, Z., Jin, B. A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell Mol Immunol 7, 11-19 (2010). https://doi.org/10.1038/cmi.2009.108

3. Uniprot(P86176

4. Khan, M., Arooj, S., & Wang, H. (2020). NK Cell-Based Immune Checkpoint Inhibition. Frontiers in immunology, 11, 167. https://doi.org/10.3389/fimmu.2020.00167

5. Harjunpaa, H., & Guillerey, C. (2020). TIGIT as an emerging immune checkpoint. Clinical and experimental immunology, 200(2), 108-119. https://doi.org/10.1111/cei.13407

6. Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W., & Smyth, M. J. (2016). Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research, 22(21), 5183-5188. https://doi.org/10.1158/1078-0432.CCR-16-0933

7. Manieri, N. A., Chiang, E. Y., & Grogan, J. L. (2017). TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends in immunology, 38(1), 20-28. https://doi.org/10.1016/j.it.2016.10.002

Long Name

T Cell Immunoreceptor with Ig and ITIM Domains

Alternate Names

VSIG9, VSTM3, WUCAM

Gene Symbol

Tigit

Additional TIGIT Products

Product Documents for TIGIT Antibody (2F7) - VHH - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for TIGIT Antibody (2F7) - VHH - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.